We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
-3.48%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$824M
AUM Growth
-$97.4M
Cap. Flow
+$20.5M
Cap. Flow %
2.49%
Top 10 Hldgs %
67.68%
Holding
37
New
9
Increased
2
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
LENZ
LENZ Therapeutics
LENZ
+$40.1M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$26.5M
3
GHRS icon
GH Research
GHRS
+$26.1M
4
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$23.4M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$19.2M

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$94M
2
TRIL
Trillium Therapeutics Inc.
TRIL
+$19.2M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$13.2M
4
ACET icon
Adicet Bio
ACET
+$10.4M
5
APTO
Aptose Biosciences, Inc.
APTO
+$9.59M

Sector Composition

Rank Sector Weight
1 Healthcare 91.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
1
Instil Bio
TIL
$48.3M
$133M 16.09%
343,254
– –
ACRS icon
2
Aclaris Therapeutics
ACRS
$726M
$80.1M 9.72%
4,563,962
+843,380
+23% +$19.2M
VTGN icon
3
VistaGen Therapeutics
VTGN
$9.89M
$50.5M 6.13%
534,910
-8,510
-2% -$631K
LENZ
4
LENZ Therapeutics
LENZ
$166M
$49.6M 6.01%
+230,374
New +$40.1M
MRNS
5
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$47.4M 5.75%
2,641,809
– –
RLMD icon
6
Relmada Therapeutics
RLMD
$557M
$44.4M 5.39%
1,387,720
+534,514
+63% +$18.6M
OLMA icon
7
Olema Pharmaceuticals
OLMA
$1B
$43M 5.21%
1,536,193
– –
CLDX icon
8
Celldex Therapeutics
CLDX
$2.99B
$41.5M 5.03%
1,240,610
– –
ALT icon
9
Altimmune
ALT
$552M
$34.5M 4.18%
3,500,000
– –
KNTE
10
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$34.3M 4.16%
1,473,014
– –
GHRS icon
11
GH Research
GHRS
$1.93B
$27.7M 3.36%
+1,275,831
New +$26.1M
CGEM icon
12
Cullinan Oncology
CGEM
$1.01B
$25.1M 3.05%
976,145
-200,000
-17% -$6.15M
CNTA
13
DELISTED
Centessa Pharmaceuticals
CNTA
$25M 3.04%
+1,127,272
New +$26.5M
PRVB
14
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$24.5M 2.97%
+2,902,744
New +$23.4M
TRIL
15
DELISTED
Trillium Therapeutics Inc.
TRIL
$19.4M 2.36%
2,001,686
-2,038,314
-50% -$19.2M
EPIX
16
DELISTED
ESSA Pharma
EPIX
$17.9M 2.17%
625,754
– –
CVRX icon
17
CVRx
CVRX
$137M
$17.7M 2.15%
+633,370
New +$17.7M
PHVS icon
18
Pharvaris
PHVS
$2.28B
$16.8M 2.04%
902,882
– –
LONA
19
LeonaBio Inc
LONA
$66.3M
$15.2M 1.84%
148,501
-20,661
-12% -$3.61M
RAPT
20
DELISTED
RAPT Therapeutics
RAPT
$12.4M 1.51%
+48,875
New +$9.13M
KURA icon
21
Kura Oncology
KURA
$800M
$12M 1.45%
575,000
– –
KROS icon
22
Keros Therapeutics
KROS
$199M
$11.6M 1.4%
272,306
-100,000
-27% -$5.42M
COGT icon
23
Cogent Biosciences
COGT
$6.65B
$8.83M 1.07%
1,088,817
– –
ALGS icon
24
Aligos Therapeutics
ALGS
$26.2M
$8.32M 1.01%
16,335
– –
AKYA
25
DELISTED
Akoya BioSciences
AKYA
$7.74M 0.94%
+400,000
New +$8.26M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q2 2021 Portfolio in Review

As of Q2 2021, VR Adviser held 37 positions worth $824M, down 11% from $922M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

VR Adviser's Q2 2021 filing shows 9 new, 2 increased, 6 reduced and 8 closed positions. Its largest new stake was LENZ Therapeutics: 230,374 shares worth $49.6M. The largest sale was Constellation Pharmaceuticals, Inc., an estimated $94M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier.

  • VR Adviser's largest Q2 2021 buy was LENZ Therapeutics: 230,374 shares worth $49.6M.
  • VR Adviser added most to Aclaris Therapeutics in Q2 2021, an estimated $19.2M increase.
  • VR Adviser's biggest Q2 2021 reduction was Trillium Therapeutics Inc., cutting an estimated $19.2M.
  • VR Adviser fully exited Constellation Pharmaceuticals, Inc. in Q2 2021, selling an estimated $94M.
  • VR Adviser's ten largest holdings make up 68% of its $824M portfolio in Q2 2021.
  • VR Adviser opened 9 new positions and closed 8 in Q2 2021.
  • VR Adviser's portfolio value fell 11% quarter-over-quarter to $824M.

Based on VR Adviser's 13F filing for Q2 2021, filed 13 Aug 2021.